Early Alzheimer’s Disease with Biomarkers of Inflammation research hub

A Randomized, Placebo-Controlled, Double-Blind Study of XPro™ in Patients with Early Alzheimer’s Disease with Biomarkers of Inflammation

This study is testing a new medicine called XPro™ for people in the early stages of Alzheimer's disease who also show signs of inflammation. We want to see if XPro™ can help improve memory and thinking skills over 24 weeks compared to a dummy pill.